{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:43:59Z","timestamp":1790873039421,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T00:00:00Z","timestamp":1299456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>Background: The calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent drugs. Both are effective in migraine but in doses much higher than would be predicted from receptor binding and other in\u00a0vitro results. This could perhaps suggest an effect of CGRP antagonists behind the blood-brain barrier (BBB), i.e. in the central nervous system (CNS).<\/jats:p>\n                  <jats:p>Methods: Comparison of doses needed for CGRP blocking effect in\u00a0vitro with dose needed in\u00a0vivo in man and monkeys. Discussion of these doses in relation to doses needed for anti-migraine activity.<\/jats:p>\n                  <jats:p>Results: In\u00a0vivo studies in monkeys and man showed that high doses compared to doses needed in\u00a0vitro are needed to block capsaicin-induced in skin blood flow, a CGRP-mediated reaction. These doses are close to those needed for anti-migraine activity.<\/jats:p>\n                  <jats:p>Conclusion: The apparently high doses of CGRP receptor antagonists, olcegepant and telcagepant needed for anti-migraine effect are not so high after all. They do not allow a conclusion as to whether CGRP antagonists act on peripheral sites or central sites in migraine.<\/jats:p>","DOI":"10.1177\/0333102411398403","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T01:49:20Z","timestamp":1299548960000},"page":"748-750","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":49,"title":["Possible site of action of CGRP antagonists in migraine"],"prefix":"10.1177","volume":"31","author":[{"given":"Peer","family":"Tfelt-Hansen","sequence":"first","affiliation":[{"name":"University of Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes","family":"Olesen","sequence":"additional","affiliation":[{"name":"University of Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,3,7]]},"reference":[{"key":"bibr1-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp168"},{"key":"bibr2-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.03.019"},{"key":"bibr3-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70090-0"},{"key":"bibr4-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707134"},{"key":"bibr5-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.346"},{"key":"bibr6-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01532-1"},{"key":"bibr7-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703110"},{"key":"bibr8-0333102411398403","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.107.130344","volume":"324","author":"Salvatore CA","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr9-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00008-4"},{"key":"bibr10-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704682"},{"key":"bibr11-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-005-1064-4"},{"key":"bibr12-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"bibr13-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705807"},{"key":"bibr14-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000286940.29755.61"},{"key":"bibr15-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61626-8"},{"key":"bibr16-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b87942"},{"key":"bibr17-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20619"},{"key":"bibr18-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2010.02.004"},{"key":"bibr19-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.163816"},{"key":"bibr20-0333102411398403","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03543.x"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102411398403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0333102411398403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102411398403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:42Z","timestamp":1777387542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0333102411398403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,7]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1177\/0333102411398403"],"URL":"https:\/\/doi.org\/10.1177\/0333102411398403","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,7]]}}}